SEC Form SC 13G/A filed by Travere Therapeutics Inc. (Amendment)
$TVTX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2025 | $34.00 → $48.00 | Buy | Citigroup |
| 6/11/2025 | $30.00 | Buy | H.C. Wainwright |
| 6/11/2025 | $35.00 → $32.00 | Buy | Citigroup |
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 10/21/2024 | $9.00 → $27.00 | Equal Weight → Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $25.00 | Neutral → Buy | Guggenheim |
| 3/27/2024 | Buy → Neutral | Guggenheim |
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bi
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 49,200 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the gran
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is
SCHEDULE 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SCHEDULE 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
144 - Travere Therapeutics, Inc. (0001438533) (Subject)
Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $48.00 from $34.00 previously
H.C. Wainwright resumed coverage of Travere Therapeutics with a rating of Buy and set a new price target of $30.00
Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $32.00 from $35.00 previously
Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bi
U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue for 3Q 2025 was $164.9 million, including U.S. net product sales of $113.2 million Retired remaining $69 million of 2025 convertible notes and achieved $40 million EU market access milestone, further strengthening financial foundation 2025 KDIGO guidelines and streamlined REMS monitoring strengthen FILSPARI's position as a foundational, nephroprotective therapy for IgAN Company well-positioned for potential FDA approval and commercial launch of FILSPARI for FSGS in 1Q26 Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)